Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
https://doi.org/10.14412/2074-2711-2016-2-117-120
Abstract
Multiple sclerosis (MS) is a demyelinating disease of the CNS, which affects mainly young able-bodied people; in this connection the problem of MS treatment assumes particular relevance. The paper reviews the main GALA (Glatiramer Acetate Low-frequency Administration) and GLACIER (Glatiramer Acetate low frequenCy safety and patient ExpeRience) clinical studies of subcutaneous glatiramer acetate (GA) 40 mg/ml three times per week (TIW).
The results of the Phase III GALA multicenter randomized placebo-controlled parallel-group study of GA 40 mg injections administered less frequently (TIW) were published in 2013. The study involved 142 centers from 17 countries, including 17 Russian centers. The GALA study proved the efficacy, safety, and good tolerability of GA 40 mg TIW in patients with relapsing-remitting MS (RRMS). The safety profile of GA 40 mg was completely consistent with the well-known profile of GA 20 mg.
The new GLACIER study was initiated to evaluate the efficiency and tolerability of treatment with GA 40 mg TIW versus GA 20 mg every day. This study confirmed that the tolerability profile of therapy with GA 40 mg TIW was better than that of GA 20 mg every day in patients with RRMS. GA 40 mg/ml TIW was approved for use in the USA, the United Kingdom, and a number of European countries for the treatment of patients with RRMS. In the Russian Federation, GA 40 mg was approved for use in September 2015.
About the Authors
N. Yu. Lashch
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics
1, Ostrovityanov St., Moscow 117997
A. N. Boiko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics
1, Ostrovityanov St., Moscow 117997
References
1. Гусева ЕИ, Завалишин ИА, Бойко АН, редакторы. Рассеянный склероз. Клиническое руководство. Москва: Реал Тайм; 2011. 528 с. [Guseva EI, Zavalishin IA, Boiko AN, editors. Rasseyannyi skleroz. Klinicheskoe rukovodstvo [Multiple sclerosis. Clinical guide]. Moscow: Real Taim; 2011. 528 p.]
2. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patient with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow up study. Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693.
3. Бойко АН, Давыдовская МВ, Демина ТЛ и др. Эффективность и переносимость глатирамера ацетата (копаксона) при длительном использовании: 10-летний опыт Московского городского центра рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;(2):86-92. [Boiko AN, Davydovskaya MV, Demina TL, et al. Efficacy and tolerability of glatiramer acetate (Copaxone) in long-term use: 10-year experience of the Moscow city center of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;(2):86-92. (In Russ.)].
4. Jonson KP, Ford CC, Lisakk RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetat therapy for multiple sclerosis:8-year data. Acta Neurol Scand. 2005 Jan;111(1):42-7.
5. Рекомендации Всероссийского общества неврологов для проведения курса лечения препаратами, изменяющими течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(7): 129-34. [Recommendations all-Russian society of neurologists to course of treatment with drugs that modify the progress of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(7):129-34. (In Russ.)].
6. Teiteibaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by synthetic polypeptide. Eur J Immunol. 1973 May;3(5):279-86.
7. Arnon R. Does glatiramer acetate unduce neurogenesis in experimental autoimmune encephalomyelitis. J Neurol. 2007;254(Suppl.2):41-6.
8. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter,doubleblind,randomized,placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patient with relapsingmultiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001 Mar;49(3):290-7.
9. Ford C, Ladkani D. Twenty years of continuous treatment of multiple sclerosis with glatiramer acetate 20 mg daily: long-term clinical results of the US open-label extension study. Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2-5 October 2013; Copenhagen, Denmark.
10. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.
11. Wolinsky JS, BorresenTE, Dietrich DW, et al. GLACIER: An openlabel, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three time weekly versus 20 mg daily in patient with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2015 Jul;4(4):370-6. doi: 10.1016/j.msard.2015.06.005. Epub 2015 Jun 14.
12. Teva Pharmaceuticals USA Inc. Copaxone (glatiramer acetate injection): prescribing information. Philadelphia (PA): Teva Pharmaceuticals; 2014.
13. Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Rev. Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175. 2015.1040768. Epub 2015 Apr 30.
14. Zivadinov R, Dwyer M, Barkay H, et al. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense «black holes»: a post hoc magnetic resonance imaging analysis. J Neurol. 2015 Mar;262(3):648-53. doi: 10.1007/s00415-014-7616-0. Epub 2014 Dec 27.
15. Zuurbier KWM, Reijs-Scheijgrond M, Visser LH. Dutch online survey Patient Reported Outcomes (PROs) MS:Improvement medication Adherence after switch of daily glatiramer acetate 20 mg/mL to 3x per week 40 mg/mL 2nd Congress of the European Academy of Neurology, Copenhagen. May 28-31 2016, P31164.
Review
For citations:
Lashch N.Yu., Boiko A.N. Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):117-120. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-117-120
Views: 916
Email this article 